This retrospective study pooled 35 outcome-evaluable Paget's sarcoma patients from two eras: the Jaffe Pathology Collection (1942–1967) and the Harvard Orthopaedic Oncology Group (1972–2001). The central question: has six decades of surgical, radiation, and chemotherapy advancement improved survival in this rare malignancy?
When an elderly Paget's patient develops new or worsening pain at a known pagetic site, malignant transformation must be top of mind. Paget's sarcoma is rare (less than 1% of all pagetoid change) but catastrophic — and its presentation is easy to attribute to the underlying disease.
The operative reality from this paper: when you confirm Paget's sarcoma, counsel patients and families that survival is approximately 14% regardless of treatment era. Modern chemotherapy and radiation have not changed this figure. This is not nihilism. It is accurate informed consent.
Key pitfall: giant cell tumors occur in florid Paget's disease and are not malignant. Do not conflate them with true Paget's sarcoma on biopsy review. The distinction changes prognosis entirely.
The authors identify why chemotherapy fails here: these patients are elderly, often have high-output cardiac failure from widespread Paget's disease, and cannot tolerate the regimens that transformed standard osteosarcoma outcomes. Location matters too. Pelvis, proximal femur, and calvarium make wide resection technically difficult or impossible, compounding the systemic barriers to cure.
This retrospective study pooled 35 outcome-evaluable Paget's sarcoma patients from two eras: the Jaffe Pathology Collection (1942–1967) and the Harvard Orthopaedic Oncology Group (1972–2001). The central question: has six decades of surgical, radiation, and chemotherapy advancement improved survival in this rare malignancy?
When an elderly Paget's patient develops new or worsening pain at a known pagetic site, malignant transformation must be top of mind. Paget's sarcoma is rare (less than 1% of all pagetoid change) but catastrophic — and its presentation is easy to attribute to the underlying disease.
The operative reality from this paper: when you confirm Paget's sarcoma, counsel patients and families that survival is approximately 14% regardless of treatment era. Modern chemotherapy and radiation have not changed this figure. This is not nihilism. It is accurate informed consent.
Key pitfall: giant cell tumors occur in florid Paget's disease and are not malignant. Do not conflate them with true Paget's sarcoma on biopsy review. The distinction changes prognosis entirely.
The authors identify why chemotherapy fails here: these patients are elderly, often have high-output cardiac failure from widespread Paget's disease, and cannot tolerate the regimens that transformed standard osteosarcoma outcomes. Location matters too. Pelvis, proximal femur, and calvarium make wide resection technically difficult or impossible, compounding the systemic barriers to cure.